US · Healthcare · Biotechnology
EPS came in at -0.70 against a street estimate of -0.60 — a miss of 16.7%.
Analysts rate DBV Technologies a buy (6 buy, 0 hold, 1 sell out of 7) with an average price target of $38.54.
| Fund | Stake |
|---|---|
| MPM Oncology Impact Management LP | 5.83% |
| Siren, L.L.C. | 2.96% |
| Vivo Capital, LLC | 2.94% |
| Perceptive Advisors LLC | 2.63% |
| Baker Bros Advisors LP | 2.33% |
| Artisan Partners Limited Partnership | 2.18% |
| UBS Group AG | 2.09% |
| Morgan Stanley - Brokerage Accounts | 1.52% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • DBV Technologies is a late-stage specialty biopharmaceutical company developing Viaskin, a skin-delivery platform for epicutaneous | 2026-10-28 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net loss was $64.5 million, compared with $33.2 million in Q3 2025; nine-month net loss was $162.5 million, compared with | 2026-10-28 |
| Company announcement · Q3 2026 HEADLINE NUMBERS • DBV Technologies S.A. announced on September 29, 2026, that it submitted a Biologics License Application (BLA) to the U.S. FDA. • | 2026-09-30 |
| Quarterly report · Q2 2026 DBV TECHNOLOGIES S.A. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $174.9 million as of June 30, 2026 (down from $194.2 million at Decem | 2026-07-16 |
| Results announced · Q3 2026 DBV TECHNOLOGIES – H1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $174.9 million as of June 30, 2026 • Funding runway: Into thi | 2026-07-16 |
| Company announcement · Q2 2026 DBV TECHNOLOGIES S.A. - 8-K SUMMARY HEADLINE NUMBERS • Company: DBV Technologies S.A., France-based biopharmaceutical company • Stock listing: Americ | 2026-06-29 |
| Board / officer change · Q2 2026 DBV TECHNOLOGIES S.A. – 8-K SUMMARY HEADLINE NUMBERS • CEO Daniel Tassé granted 4,060,000 Performance Share Units (PSUs) on June 5, 2026 • 2,900,000 | 2026-06-05 |
| Charter / bylaws change · Q2 2026 DBV TECHNOLOGIES S.A. – 8-K FILING SUMMARY (JUNE 3, 2026) HEADLINE NUMBERS • Annual General Meeting held June 3, 2026 with 39 shareholder proposals | 2026-06-03 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for DBV Technologies — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.